Skip Navigation
Skip Website Tools
Zonghui Hu photo

Contact Info

Zonghui Hu, Ph.D.
6700B Rockledge Drive
Bethesda, MD 20892-7609
Phone: 301-451-2434
Fax: 301-480-0912
huzo@niaid.nih.gov

Overnight mail address:
6700-A Rockledge Drive, Room 5231
Bethesda, MD 20817

Biostatistics Research Branch (BRB)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Zonghui Hu, Ph.D.

Mathematical Statistician

Interests

Functional data analysis, semiparametric models, measurement error models, longitudinal data analysis, generalized models, biostatistics.

Additional Information

Curriculum Vitae (PDF)

Selected Publications

Statistical Publications

  • Hu Z, Follmann D, Qin J (2011). Semiparametric double balancing score estimation for incomplete data with ignorable missingness.  Journal of American Statistical Association, to appear.
  • Hu Z, Follmann D, Qin J (2011). Dimension reduced kernel estimation for distribution function with incomplete data. Journal of Statistical Planning and Inference, 141: 3084-3093.
  • Hu Z, Follmann D, Qin J (2010). Semiparametric dimension reduction estimation for mean response with missing. Biometrika, 97: 301-319.
  • Brittain E, Hu Z (2009). Non-inferiority trial design and analysis with an ordered three-level categorical endpoint. Journal of Biopharmaceutical Statistics, 19: 685-699.
  • Hu Z, Qin J, Follmann D.(2008). Semiparametric two-sample change-point model. Journal of Royal Statistical Society Series C, 57: 589-607.
  • Hu Z, Wang N (2008). Semiparametric mixed-effects model with latent covariate in Colon carcinogenesis study. Statistics and Its Interface, 1: 75-86.
  •  Hu Z, Qin J, Follmann D, Dewar R (2008). Nonparametric likelihood approach for assessing the accordance between two measurements and its application to viral load determination with limit of detection. Statistics in Medicine, 27: 4489-4501.
  • Hu Z, Follmann D(2007). Statistical methods for active extension trials. Statistics in Medicine, 26:2433-2448.
  • Hu Z, Wang N, Carroll R (2004). Profile-Kernel versus backfitting in the partially linear models for longitudinal/clustered data. Biometrika, 91:251-262.

Medical Publications

  • Ledgerwood JE, Wei CJ,  Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Yassine H, Bailer R, Tumpey TM.  Koup RA, Mascola JR, Nabel GJ, Graham BS1 and the VRC 306 Study Team (2011). DNApriming improves influenza vaccine immunogenicity in humans. Lancet, 11:912-924.
  • Hodge JN, Srinivasula S, Hu Z,  Read SW, Porter  BO. Mican J, Paik C, Di Mascio M, Sereti I (2011). Decreases in IL-7 levels during ART suggest a primary mechanism of receptor-mediated clearance with IL-7 levels normalizing despite persistent CD4 lymphopenia. Blood, 118:3244-3253.
  • Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Mutchaba G, Sangweni P, Metcalf J, Pool N, Orsega S, Emery S on behalf of the PHIDISA II study team (2011). Impact of 3TC on HIV and HBV related outcomes in HIV/HBV individuals in a randomized clinical trial of antiretroviral therapy in South Africa. AID, 14:1727-1735.
  • Dlamini J, Hu Z, Morris L, Somaroo H, Ledwaba J, Maldarelli F, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A, and the Phidisa Study Group (2011). Genotypic Resistance at Viral Rebound among Patients Who Received Lopinavir/ritonavir- or Efavirenz-Based First Antiretroviral Therapy in South Africa. Journal of Acquired immune Deficiency Syndrome, 58:304-308.
  • Dlamini J, Hu, Z,  Somaroo H, Highbarger H, Sangweni P, Follman D, Dewar R, Pau A (2011). Lack of effect from a previous single dose of Nevirapine on virologic and immunologic responses after 6 months of antivetroviral regimens containing efavirenz or lopinavir-ritonavir. Pharmacotherapy, 31: 158-163.
  • Sneller MC, Hu Z, Langford CA (2011). A Randomized Controlled Trial of Rituximab Following Failure of Antiviral Therapy for Hepatitis C-Associated Cryoglobulinemic. Arthritis & Rheumatism.
  • Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS and the VRC 205 Study Team (2010). A Replication Defective Recombinant Ad5 Vaccine Expressing Ebola Virus GP Is Safe and Immunogenic in Healthy Adults. Vaccine, 29(2): 304-313.
  • Dlamini JN, Hu  Z, Somaroo, H, Highbarger HC, Follmann DA, Dewar RL, Pau AK (2010). No Effect of Prior Single-Dose Nevirapine on 6-Month Virologic and CD4 Responses After Commencement of Efavirenz- or Lopinavir/ritonavir-Based Regimen in a Cohort of South African HIV+ Women. Pharmacotherapy, In press.
  • Komarow H, Hu Z, Brittain E, Uzzaman A, Gaskins D, Metcalfe DD (2009). Serum tryptase levels in atopic and non-atopic children. Journal of Allergy and Clinical Immunology, 124: 845-848.
  • Hill VL, Simpson VZ, Higgins J, Hu Z, Stevens RA, Metcalf J, Baseler M (2009). Evaluation of the Performance of the Sysmex XT-2000i Hematology Analyzer with Whole Bloods Stored at Room Temperature. Lab Medicine, 40: 709-718.
  • Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane C (2008). HIV infection associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 105: 19851-19856.
  • Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Vailati M, Lempicki RA, Mican JA, Suffredini A, Masur H, Polis MA, Kottilil S (2008). Identification of novel markers for liver fibrosis in HIV/HCV co-infected individuals using genomics-based approach. AIDS, 22: 1433–1439.
  • Highbarger HC, Hu Z, Kottilil S, Metcalf JA, Polis MA, Vasudevachari MB, Lane HC, Dewar RL (2007). Comparison of the Abbott 7000 and Bayer 340 systems for measurement of Hepatitis C viral load. Journal of Clinical Microbiology, 45: 2808-2812.

back to top

Last Updated December 05, 2011